A61K 47/68
The modifying agent being an antibody, an immunoglobulin or a fragment thereof
Official title: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K47/68 (The modifying agent being an antibody, an immunoglobulin or a fragment thereof) appears on 7,141 US grants and 12,542 published applications in this corpus.
Search patents in A61K- Granted patents
- 7,141
- Published applications
- 12,542
- Assignees
- 3,170
- Inventors
- 18,606
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 2 | 0 |
| 1978 | 2 | 0 |
| 1979 | 2 | 0 |
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 7 | 0 |
| 1983 | 9 | 0 |
| 1984 | 10 | 0 |
| 1985 | 4 | 0 |
| 1986 | 6 | 0 |
| 1987 | 18 | 0 |
| 1988 | 19 | 0 |
| 1989 | 24 | 0 |
| 1990 | 36 | 0 |
| 1991 | 42 | 0 |
| 1992 | 55 | 0 |
| 1993 | 53 | 0 |
| 1994 | 42 | 0 |
| 1995 | 35 | 0 |
| 1996 | 67 | 0 |
| 1997 | 95 | 0 |
| 1998 | 135 | 0 |
| 1999 | 97 | 0 |
| 2000 | 83 | 0 |
| 2001 | 76 | 31 |
| 2002 | 77 | 126 |
| 2003 | 73 | 200 |
| 2004 | 50 | 174 |
| 2005 | 49 | 205 |
| 2006 | 85 | 198 |
| 2007 | 78 | 169 |
| 2008 | 71 | 189 |
| 2009 | 120 | 246 |
| 2010 | 121 | 243 |
| 2011 | 118 | 280 |
| 2012 | 147 | 266 |
| 2013 | 184 | 315 |
| 2014 | 208 | 442 |
| 2015 | 238 | 498 |
| 2016 | 327 | 669 |
| 2017 | 390 | 655 |
| 2018 | 383 | 710 |
| 2019 | 458 | 771 |
| 2020 | 446 | 726 |
| 2021 | 484 | 864 |
| 2022 | 426 | 832 |
| 2023 | 446 | 933 |
| 2024 | 447 | 1033 |
| 2025 | 467 | 963 |
| 2026 | 326 | 804 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 47/6835The modifying agent being an antibody or an immunoglobulin bearing at least5,444
- A61K 47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent4,022
- A61K 47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker1,108
- A61K 47/6891Pre-targeting systems involving an antibody for targeting specific cells550
Recent patents
- Muscle targeting complexes and formulations for treating facioscapulohumeral muscular dystrophy6 Oct 2026US 12,752,013 B2Dyne Therapeutics, Inc.
- Disruption of CD28-sialoside ligand complexes to enhance T cell activation6 Oct 2026US 12,752,014 B2The Scripps Research Institute
- Anti-galectin 3 antibodies and their use in epilepsy and related diseases6 Oct 2026US 12,752,015 B2Sunmed Therapeutic Limited
- Anti-Nectin-4 antibody, conjugate including the same, and application thereof6 Oct 2026US 12,753,230 B2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Bifunctional molecules for lysosomal targeting and related compositions and methods6 Oct 2026US 12,753,239 B2The Board of Trustees of the Leland Stanford Junior University
- Prefusion-stabilized human parainfluenza virus 3 f proteins8 Oct 2026US 2026/0306613 A1Board of Regents, The University of Texas System
- Novel conjugate of immune-stimulating il-2 analog and preparation method thereof8 Oct 2026US 2026/0306646 A1Hanmi Pharm. Co., Ltd.
- Asgpr binders and compositions and methods thereof8 Oct 2026US 2026/0306647 A1Biohaven Therapeutics Ltd.
- Delivery of dual payload of mmaf or mmae and tlr7 agonists8 Oct 2026US 2026/0306648 A1The Research Foundation for The State University of New York
- Methods for treating patients with locally advanced or metastatic urothelial cancer with antibody drug conjugates (adc) that bind 191p4d12 proteins in combination with pembrolizumab8 Oct 2026US 2026/0306649 A1Agensys, Inc.
Most cited
By later US patents
- Polypeptide variants1,041US 6,194,551 B1Genentech, Inc. · 2001
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Chimeric antibody with specificity to human B cell surface antigen853US 5,500,362 AXoma Corporation · 1996
- Cytotoxic agents comprising maytansinoids and their therapeutic use805US 5,208,020 AImmunoGen, Inc. · 1993
- Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma744US 5,736,137 AIDEC Pharmaceuticals Corporation · 1998